We suggest that therapeutic approaches with PAC1 agonists under real-world clinical conditions could complement statin and PCSK9 (proprotein convertase subtilisin/kexin type 9) therapy of patients at risk of developing atherosclerosis-related pathologies. This evidence concerns the gene ADCYAP1R1 and atherosclerosis.